The usefulness of cytogenetic parameters, level of p53 protein and endogenous glutathione as intermediate end-points in raw betel-nut genotoxicity

Human and Experimental Toxicology

Volumn 22, Issue 7, 2003, Pages 363-371

  Kumpawat, K ^a   Chatterjee, Anupam ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

Author keywords

Biomarkers; Cell cycle delay; Chromosome aberrations; Mutagen sensitivity; Sister chromatid exchanges

Indexed keywords

ALKALOID DERIVATIVE; BIOLOGICAL MARKER; BLEOMYCIN SULFATE; CARCINOGEN; DNA; FREE RADICAL; GLUTATHIONE; OXYGEN; POLYPHENOL; PROTEIN P53; TANNIN;

ADULT; AGED; ARTICLE; BETEL NUT; BLOOD LEVEL; CANCER SUSCEPTIBILITY; CARCINOGENICITY; CELL CYCLE G2 PHASE; CELL KINETICS; CHROMATID ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA DAMAGE; FEMALE; GENETIC DAMAGE; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HEALTH HAZARD; HUMAN; HUMAN CELL; IN VITRO STUDY; INDIAN; MALE; MASTICATION; MODULATION; MOUTH DISEASE; MUTAGENIC ACTIVITY; PERIPHERAL LYMPHOCYTE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; WESTERN BLOTTING;

ADULT; AGED; ARECA; BIOLOGICAL MARKERS; CELL CYCLE; CELLS, CULTURED; CYTOGENETIC ANALYSIS; DNA DAMAGE; ENDPOINT DETERMINATION; FEMALE; GLUTATHIONE; HUMANS; INDIA; MALE; MASTICATION; MIDDLE AGED; MUTAGENICITY TESTS; MUTAGENS; PLANT LEAVES; TUMOR SUPPRESSOR PROTEIN P53;

PIPER BETEL;

EID: 0042524652     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. IARC. IARC monographs on the evaluation of the carcinogenic risks to humans Vol. 37. Tobacco habits other than smoking: Betel-quid and areca nut chewing: and some related nitrosamines. Lyon: IARC, 1985: 141-200.
2. Nair, UJ, Ohshima H, Pignatelli B, Friesen M, Malaveille C, Calmels S, Bartsch H. Modifiers of endogenous carcinogen formation: studies on in vivo nitrosation in tobacco users. In Hoffmann D, Harris CC eds. New aspects of tobacco carcinogenesis, Banbury Report 23. New York: Cold Spring Harbor Laboratory Press, 1986:. 45-61.
3. Majumdar AM., Kapadi AH, Pendse GS. Pharmacological properties In Bavappa KVA ed. The areca nut palm, Central Research Institute, 1982: 245-61.
4. Jeng JH, Chang MC, Hahn LJ. Role of areca nut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives (Review). Oral Oncol 2001; 37: 477-92.
5. Panigrahi GB, Rao AR. Study of the genotoxicity of the total aqueous extract of betel nut and its tannins. Carcinogenesis 1996; 7: 37-39.
6. Deb S, Chatterjee A. Influence of buthionine sulfoximine and reduced glutathione on areco-line-induced chromosomal damage and sister chromatid exchange in mouse bone marrow cells in vivo. Mutagenesis 1998; 13: 243-48.
7. Shirname IP, Menon MM, Bhide SV. Mutagenicity of betel quid and its ingredients using mammalian test systems. Carcinogenesis 1984; 5, 501-503.
8. Ranadive KJ, Ranadive SN, Shivapurkar NM, Gothoskar SV. Betel quid chewing and oral cancer: experimental studies on hamsters. Int J Cancer 1979; 24: 835-43.
9. Bhide SV, Shivapurkar NM, Gothoskar SV, Ranadive KJ. Carcinogenicity of betel quid ingredients: feeding mice with aqueous extract and the polyphenolic fraction of betel nut. Br J Cancer 1979; 40: 922-26.
10. Ranadive KJ, Gothoskar SV, Rao AR, Tezabwalla BV, Ambaye RY. Experimental studies on betel nut and tobacco carcinogenicity. Int J Cancer 1976; 17: 469-76.
11. Chatterjee A, Jacob-Raman M. Modifying effect of reduced glutathione on X-ray induced chromosome aberrations and cell cycle delay in muntjac lymphocytes in vitro. Mutat Res 1986; 175: 73-82.
12. Chattopadhyay A, Deb S, Chatterjee A. Modulation of the clastogenic activity of γ-irradiation in buthionine sulfoximine mediated glutathione depleted mammalian cells. Int J Radiat Biol 1999; 75: 1283-91.
13. DevGiri S, Chatterjee A. Modulation of mitomycinC induced sister chromatid exchanges and cell cycle delay by buthionine sulfoximine and reduced glutathione in mouse bone marrow cells in vivo. Mutat Res 1998; 413: 227-34.
14. Syng-ai A, Basu Baul T, Chatterjee A. Antiproliferative and cytotoxic effect of a novel organo-tin compound on mammalian cells both in vivo and in vitro. Mutat Res 2002; 513: 49-59.
15. Chatterjee A, Jacob-Raman M, Mohapatra B. Potentiation of bleomycin induced chromosome aberrations by the radioprotector reduced glutathione. Mutat Res 1989; 214: 207-13.
16. Chattopadhyay A, Choudhury S, Chatterjee A. Modulation of the clastogenic activity of bleomycin by reduced glutathione, glutathione-ester and buthionine sulfoximine. Mutagenesis 1997; 12: 221-25.
17. Sundqvist K, Lui Y, Nair J, Bartsch H, Arvidson K, Grafstrom RC. Cytotoxic and genotoxic effects of areca nut related compound in cultured human buccal epithelial cells. Cancer Res 1989; 49: 5294-98.
18. Chatterjee A, Deb S. Genotoxic effects of arecoline either by peritoneal or oral route in murine bone marrow cells and the influence of N-acetylcysteine. Cancer Lett 1999; 13: 23-31.
19. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Ann Rev Med 1996; 47: 285-301.
20. Liloglou T, Scholes AGM, Spandidos DA, Vaughan ED, Jones AS, Field JK. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Res 1997; 57: 4070-74.
21. Kaur J, Srivastava A, Ralhan R. Overexpression of p53 protein in betel and tobacco related human oral dysplasia and squamous cell carcinoma in India. Int J Cancer 1994; 58: 340-45.
22. Sharan RN. Association of betel nut with carcinogenesis. Cancer J 1996; 9: 13-19.
23. Stich HF, Hornby AP, Dunn BP. A pilot beta-carotene intervention trial with Inutia using smokeless tobacco. Int J Cancer 1985; 36: 321-27.
24. Pandita, TK, Hittelman WN. Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. Int J Cancer 1995; 61: 738-43.
25. Goto K, Akematsu T, Shimagu H, Suigiyama, T. Simple differential giemsa staining of sister chromatids after treatment with photosensitive dyes and exposure to light and the mechanism of staining. Chromosoma, 1975; 53: 223-30.
26. Akerboom TPS, Sies H. Assay of glutathione, glutathione disulfide and glutathione mixed disulfides in biological samples. Methods Enzymol 1981; 77: 373-82.
27. Boyum A. Separation of leucocyte from blood and bone marrow. Scand J Clin Lab Invest 1968; 21: 77-89.
28. Snedecor GW, Cochran WG. Statistical methods, sixth edition. Iowa: Iowa State Press, 1967.
29. Margolin BH, Shelby MD. Sister chromatid exchanges: A reexamination of the evidence for sex and race differences in humans. Environ Mutagen, 1985; 7 (Suppl. 4): 63-72.
30. Husum B, Wulf HC, Neibuhr E. Sister chromatid exchange frequency correlates with age, sex and cigarette smoking in a 5-year material of 533 healthy adults. Hereditas 1986; 105: 17-21.
31. Adhvaryu SG, Dave BJ, Trivedi AH. Cytogenetic surveillance of tobacco-areca nut (mava) chewers, including patients with oral cancer and premalignant conditions. Mutat Res, 1991; 261: 41-49.
32. Adhvaryu SG, Dave BJ, Trivedi AH, Cytogenetic surveillance of tobacco-areca nut (mava) chewers, including patients with oral cancer and premalignant conditions. Mutat Res 1991; 261: 41-49.
33. Bonassi S, Hagmar L., Strömberg U, Montagud AH, Tinnerberg H, Forni A, Heikkilä P, Wanders S, Wilhardt O, Hansteen I-L., Knudsen LE, Norppa H for the European study group on cytogenetic biomarkers and health. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res 2000; 60: 1619-25.
34. Chagnati RSK, Schonberg S, German J. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. Proc Natl Acad Sci USA 1974; 71: 4508-11.
35. Buckton KE, Hamilton GE, Paton L, Langlands AO. Chromosome aberrations in irradiated ankylosing spondylitis patients. In HJ Evans, DC Lloyd ed. Mutagen-induced chromosome damage in man. Edinburgh: Edinburgh University Press, 1978: 142-50.
36. IARC. Overall evaluation of carcinogenicity: an updating of IARC monographs. In Monographs of evaluation of carcinogenic risk of chemicals in humans; supplement 7, volumes 1 to 42. Lyon: International Agency for Research on Cancer, 1987.
37. Stich HF, Oshima H, Pignatelli B, Michelson J, Bartsch H. Inhibitory effect of betel nut extract on endogenous nitrosation in human. J Natl Cancer Inst 1983; 70:1047-50.
38. Rosin MP. The influetice of pH on the convertogenic activity of plant phenolics. Mutat Res 1984; 1135: 109-13.
39. Nair UJ, Floyd RA, Nair J, Bussachini V, Friesen M, Bartsch H. Formation of reactive oxygen species and 8-OH-dG in DNA in vitro with betel quid ingredients. Chem Biol Interact 1987; 63: 157-69.
40. Cerutti PA. Prooxidant states and tumour promotion. Science 1985; 227: 375-81.
41. Hoffmann D, Brunnemann KD, Prokopczyk B, Djordjevic MV. Tobacco-specific H-nitrosamines and areca derived N-nitrosamines: chemistry, biochemistry, carcinogenicity and relevance to humans. J Toxicol Environ Health 1994; 41: 1-52.
42. Nery R. The metabolic interconversion of arecoline and arecoline 1-oxide in the rat. Biochem J 1971; 122: 503-508.
43. Jeng JH, Lan WH, Hahn LJ, Hsieh CC, Kuo MYP. Inhibition of the migration, attachment, spreading, growth and collagen synthesis of human gingival fibroblasts by arecoline, a major areca alkaloid in vitro. J Oral Oathol Med 1996; 25: 371-75.
44. Wong DYK, Hsiao YL, Poon CK et al. Glutathione concentration in oral cancer tissues. Cancer Lett 1994; 81: 111-16.
45. Sundqvist K, Lui Y, Nair J, Bartsch H, Arvidson K, Grafstrom RC. Cytotoxic and genotoxic effects of areca nut related compound in cultured human buccal epithelial cells. Cancer Res 1989; 49: 5294-98.
46. Van Wyk CW, Oliver A, Hoal-Van Helden EG, Grobler-Rabie AF. Growth of oral and skin fibroblasts from patients with oral submucous fibrosis. J Oral Pathol Med 1995; 24: 349-53.
47. Boyland E, Nery R. Mercapturic acid formation during metabolism of arecoline and arecaidine in the rat. Biochem J 1969; 113: 123-30.
48. Adhvaryu SG, Trivedi AH, Jani KH, Vyas RC, Dave BJ. Genotoxic effects of ketamine on CHO cells. Arch Toxicol 1986; 59: 124-25.
49. Rainaldi R, Mariani T. The distribution of induced sister chromatid exchanges: a tool for identifying agents directly interacting with DNA. Mutat Res 1982; 103: 333-37.
50. Hsu TC, Johnston DA., Cherry L.M, Ramkissoon D, Schantz SP, Jessup JM et al. Sensitivity to genotoxic effects of bleomycin in humans possible relationship to environmental carcinogenesis. Int J Cancer 1989; 43: 403-409.
51. Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer (Letter). Lancet 1994; 344: 1444.
52. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-20.
53. Zhan Q, Bae I, Kastan MB, Fornace AJ. The p53-dependent gamma ray response of GADD45. Cancer Res. 1994; 54: 2755-60.
54. Smith ML, Chen IT, Zhan Q, O'Connor PM, Forance AJ. Involvement of the p53 tumour suppressor in repair of UV-type damage. Oncogene 1995; 10: 1053-59.
55. Kastan MB, Onyckwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
56. Ahomadegbe JC, Barrios M, Fogel S, Bihan MLL, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastasis: absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217-27.
57. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321-26.
58. Bennet WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, Kusters I, Resau JG, Trump BF, Lane DP. Harris CC. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6092-97.
59. Mc Michael A, Hall J. The use of biological markers as predictive early-outcome measures in epidemiological research. In P Toniolo, P Boffetta, DEG Shuker, H Rothman, B Hulka, N Pearce eds. Application of biomarkers in cancer epidemiology. Lyon: IARC, 1997: 281-89.
60. Rothman N et al. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epidemiol Biomarkers and Prev 1995; 4: 301-11.